Tamara van Donge

Introduction 21 1 22. Wilson JT. An update on the therapeutic orphan. Pediatrics. 1999;104(3 Pt 2):585-590. 23. Wilson JT. Pragmatic assessment of medicines available for young children and pregnant or breast-feeding women. Basic and therapeutic aspects of perinatal pharmacology. 1975:411-421. 24. Sachs AN, Avant D, Lee CS, Rodriguez W, Murphy MD. Pediatric Information in Drug Product Labeling. JAMA. 2012;307(18):1914-1915. 25. Nir-Neuman H, Abu-Kishk I, Toledano M, Heyman E, Ziv-Baran T, Berkovitch M. Unlicensed and Off- Label Medication Use in Pediatric and Neonatal Intensive Care Units: No Change Over a Decade. Adv Ther. 2018;35(7):1122-1132. 26. Baum VC, Bax R, Heon D, Yang Z, Sakiyama M. Pediatric drug regulation: international perspectives. Pediatric Anesthesia. 2019;29(6):572-582. 27. Hawcutt DB, Smyth RL. The new European regulation on pediatric medicines. In: Springer; 2008. 28. EMA. European Pediatric Regulation. https://ec.europa.eu/health//sites/health/files/files/ eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf. Published 2007. Accessed 28th January 2021. 29. Tomasi PA, Egger GF, Pallidis C, Saint-Raymond A. Enabling development of paediatric medicines in Europe: 10 years of the EU paediatric regulation. Pediatric Drugs. 2017;19(6):505-513. 30. Philip AG. The evolution of neonatology. Pediatric research. 2005;58(4):799-815. 31. Gershanik J, Boecler B, Ensley H, McCloskey S, George W. The gasping syndrome and benzyl alcohol poisoning. New England Journal of Medicine. 1982;307(22):1384-1388. 32. Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. Br Med J (Clin Res Ed). 1983;287(6403):1424-1427. 33. McCune SK, Mulugeta YA, Baer GR. Collaboration in regulatory science to facilitate therapeutic development for neonates. Current pharmaceutical design. 2017;23(38):5801-5804. 34. Ette EI, Williams PJ. Pharmacometrics: the science of quantitative pharmacology. John Wiley & Sons; 2013. 35. Manolis E, Pons G. Proposals for model‐based paediatric medicinal development within the current European Union regulatory framework. British journal of clinical pharmacology. 2009;68(4):493-501. 36. Samardzic J, Allegaert K, Wilbaux M, Pfister M, van den Anker JN. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period. Expert opinion on drug metabolism & toxicology. 2016;12(4):367-375. 37. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clinical pharmacokinetics. 2008;47(4):231-243. 38. Vinks A, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: application of pharmacometrics to define the right dose for children. Clinical Pharmacology & Therapeutics. 2015;98(3):298-308. 39. Mould DR, Upton R. Basic concepts in population modeling, simulation, and model‐based drug development. CPT: pharmacometrics & systems pharmacology. 2012;1(9):1-14. 40. Neely M, Bayard D, Desai A, Kovanda L, Edginton A. Pharmacometric modeling and simulation is essential to pediatric clinical pharmacology. The Journal of Clinical Pharmacology. 2018;58:S73-S85.